UnknownNot Applicable

AMH and Functional Hypothalamic Amenorrhea

Italy50 participantsStarted 2023-06-16

Plain-language summary

The purpose of this study is to analyze AMH levels in patients with prolonged FHA (more than 2 years). Based on previous studies, we can assume that prolonged FHA may mimic a condition of primary hypogonadotropic hypogonadism, due to a lasting interruption of gonadotropin release. Furthermore, after the resumption of the spontaneous menstrual cycle, we will reanalyze AMH levels, which we hypothesize to find higher. If our hypotheses are confirmed correct, we could support the thesis that AMH is not a good index of ovarian reserve in patients with functional hypothalamic amenorrhea.

Who can participate

Age range15 Years – 34 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women aged 15-34 years. * Diagnosis of functional hypothalamic amenorrhea (for at least 2 years). * Signature of informed consent. Exclusion Criteria: * Polycystic ovary syndrome * Taking oral contraceptives in the previous three months * Other clinically relevant endocrinopathies * positive MAP-test (Medroxyprogesterone acetate test) * Estroprogestin replacement therapy * Autoimmune disorders * Failure to sign informed consent

What they're measuring

AMH assay

Timeframe: 12 months

Trial details

NCT IDNCT05921877

SponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-16

View on ClinicalTrials.gov More Amenorrhea Secondary trials